Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 9, 2026

T-maze Forced Alternation and Left-right Discrimination Tasks for Assessing Working and Reference Memory in Mice
17:45

T-maze Forced Alternation and Left-right Discrimination Tasks for Assessing Working and Reference Memory in Mice

Published on: February 26, 2012

Tolterodine does not affect memory assessed by passive-avoidance response test in mice.

Gregg D Cappon1, Brian Bush, Donald Newgreen

  • 1Pfizer Global Research and Development, Drug Safety Research and Development, Groton, CT 06340, United States. gregg.d.cappon@pfizer.com

European Journal of Pharmacology
|November 23, 2007
PubMed
Summary

Tolterodine, an overactive bladder medication, did not impair memory in a mouse model. This study suggests tolterodine (an antimuscarinic) does not negatively affect cognitive function, unlike some other medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methanol toxicity from inhalational abuse of a methyl acetate-containing nail polish remover.

The American journal of emergency medicine·2026
Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026
Same author

BPI26-022: Reducing Diagnosis-to-Treatment Times in Cancer Care: A Community-Engaged Approach to Health Equity.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

QIM26-291: Advancing Health Equity in Cancer Care Through Social Drivers of Health Integration.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

QIM26-291: Advancing Health Equity in Cancer Care Through Social Drivers of Health Integration.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

BPI26-022: Reducing Diagnosis-to-Treatment Times in Cancer Care: A Community-Engaged Approach to Health Equity.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Area of Science:

  • Pharmacology
  • Neuroscience
  • Urology

Background:

  • Antimuscarinics are primary treatments for overactive bladder.
  • Central nervous system-permeable antimuscarinics like scopolamine can cause cognitive impairment.
  • Tolterodine is an antimuscarinic used for overactive bladder.

Purpose of the Study:

  • To evaluate the effect of tolterodine on memory in a mouse passive-avoidance model.
  • To determine if tolterodine disrupts cognitive function.

Main Methods:

  • A passive-avoidance test was used in mice.
  • Mice received tolterodine (1 or 3 mg/kg) or scopolamine.
  • Memory was assessed by latency to cross and percentage of animals crossing.

Main Results:

More Related Videos

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice
08:52

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice

Published on: August 30, 2017

Related Experiment Videos

Last Updated: Jul 9, 2026

T-maze Forced Alternation and Left-right Discrimination Tasks for Assessing Working and Reference Memory in Mice
17:45

T-maze Forced Alternation and Left-right Discrimination Tasks for Assessing Working and Reference Memory in Mice

Published on: February 26, 2012

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice
08:52

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice

Published on: August 30, 2017

  • Tolterodine (1 or 3 mg/kg) did not affect memory in mice.
  • Scopolamine induced a memory deficit.
  • At doses six-fold higher than therapeutic exposure, tolterodine showed no cognitive disruption.

Conclusions:

  • Tolterodine does not appear to disrupt cognitive function in the mouse passive-avoidance model.
  • These findings suggest tolterodine is a safe option for overactive bladder treatment regarding cognitive side effects.